ReviewNutrition & diabetes2024
Unmet needs in the treatment of type 1 diabetes: why is it so difficult to achieve an improvement in metabolic control?
Review in Nutrition & diabetes, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed.
- Impact of system updates for sensor-augmented pump therapy on glycemic management in Japanese individuals with type 1 diabetes (SAP-J T1D study).Journal of diabetes investigation · 2026Article
- Co-Designing Peer Support Interventions for Adolescents with Type 1 Diabetes and Their Caregivers: A Novel Integration of Community-Based Participatory Research and Human-Centred Design Thinking.Hormone research in paediatrics · 2026Article
- A CD40-targeting peptide, OPT501, modulates inflammation in canine diabetes mellitus improving clinical outcomes.Frontiers in immunology · 2026Article
- Nanoparticle-Based Oral Insulin Delivery: Challenges, Advances, and Future Directions.Pharmaceutics · 2025Review
- Networks and clusters of immunometabolic biomarkers and depression-associated features in middle-aged and older community-dwelling US adults with and without depression.Brain, behavior, & immunity - health · 2025Article
- Dietary Interventions for Adults with Type 1 Diabetes: Clinical Outcomes, Guideline Alignment, and Research Gaps-A Scoping Review.Nutrients · 2025Article
- Integrative analysis identifies shared therapeutic pathways in thyroid eye disease and diabetes mellitus.Scientific reports · 2025Article
- Revolutionary self-powered transducing mechanism for long-lasting and stable glucose monitoring: achieving selective and sensitive bacterial endospore germination in microengineered paper-based platforms.Microsystems & nanoengineering · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The development of advanced diabetes technology has permitted persons with type 1 diabetes mellitus to improve metabolic control significantly, particularly with the development of advanced hybrid closed-loop systems which have improved the quality of life by reducing hypoglycemia, decreasing macroangiopathy and microangiopathy-related complications, ameliorating HbA1c and improving glycemic variability. Despite the progression made over the past few decades, there is still significant margin for improvement to be made in terms of attaining appropriate metabolic control. Various factors are responsible for poor glycemic control including inappropriate carbohydrate counting, repeated bouts of hypoglycemia, hypoglycemia unawareness, cutaneous manifestations due to localized insulin use and prolonged use of diabetes technology, psychosocial comorbidities such as eating disorders or 'diabulimia', the coexistence of insulin resistance among people with type 1 diabetes and the inability to mirror physiological endogenous pancreatic insulin secretion appropriately. Hence, the aim of this review is to highlight and overcome the barriers in attaining appropriate metabolic control among people with type 1 diabetes by driving research into adjunctive treatment for coexistent insulin resistance and developing new advanced diabetic technologies to preserve β cell function and mirror as much as possible endogenous pancreatic functions.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.